Novogen Limited has been advised that the licensee of its soy related patents The Solae Company (formally known as Protein Technologies International Inc.) has filed a patent infringement suit against Archer Daniel Midland Company and Amerifit Nutrition Inc.
The Solae Company is part of an alliance between DuPont and Bunge Limited.
The lawsuit asserts that ADM's Novasoy isoflavone products and the Estroven health supplement products marketed by Amerifit infringe certain patent rights of The Solae Company. Novogen's recently granted U.S. patent which covers the use of certain isoflavones for the treatment of menopausal symptoms, forms part of the patent portfolio available to Solae.
Solae is seeking court orders that ADM and Amerifit stop selling and making the products claimed to infringe the patents and is seeking damages. The amount of damages sought is not specified.
Novogen's Managing Director, Christopher Naughton, said the inclusion of Novogen's recently granted U.S. patent in this action by Solae confirms the commercial utility of Novogen's expanding intellectual property portfolio.
Novogen markets internationally three of its own proprietary dietary supplements, Promensil for the treatment of the symptoms of menopause, Rimostil for the maintenance of bone and cholesterol health in post- menopausal women and Trinovin for the maintenance of prostate and urinary health for men.